In particular, reduced expression of CCND2 was found in more aggressive prostate tumors characterized by high Gleason score and elevated PSA levels, suggesting that it could be an indicator of increased risk of relapse [51], while downregulation of AXIN2 and BMPR2 was associated with high tumor grade, invasiveness, and recurrence [52,53]. This evidence concerns the gene CCND2 and prostate neoplasm.